Effect of Trimethylcolchicinic Acid Methyl Ether d-Tartrate (TMCA) on Hodgkin’s and Non-Hodgkin’s Lymphoma

Publisher Website
Google Scholar
Abstract
TMCA (NSC-36354) was administered daily by mouth to 71 patients with malignant lymphomas. Partial (> 50%) responses were observed in 11 of 37 patients with Hodgkin''s disease, 2 of 22 patients with lymphocytic lymphoma, and 1 of 2 patients with mixed cell lymphoma. One complete and 3 partial responses were noted in 9 patients with histiocytic lymphoma. Responses lasted from 1-91+ mo. (median: 4 mo.) and occurred in patients whose disease was resistant to alkylating agents, vinblastine, vincristine, procarbazine, prednisone or BCNU [1,3-bis(2-chloroethyl)-1-nitrosourea]. Toxic effects included leukopenia, thrombocytopenia, nausea, diarrhea, stomatitis, alopecia and dermatitis.